Emergent says it has disposed of spoilt COVID-19 vaccine batch
- Wall Street ends mixed despite bumper big-bank earnings
- Coinbase (COIN) Soars 52% in Public Debut
- Thermo Fisher Scientific (TMO) Nears Deal to Buy PPD, Inc. (PPD) for More Than $15 Billion -DJ
- Dell Technologies (DELL) Announces Planned VMware (VMW) Spin-Off
FILE PHOTO: A nurse draws from a vial of Johnson & Johnson coronavirus disease (COVID-19) vaccine, in Los Angeles, California, U.S., March 25, 2021. REUTERS/Lucy Nicholson/File Photo
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Reuters) - Johnson & Johnson's manufacturing partner Emergent Biosolutions said on Thursday that it had discarded the single batch of COVID-19 drug substance that did not meet specifications.
J&J on Wednesday said it had found a problem with a batch of the drug substance for its COVID-19 vaccine being produced at Emergent's site in Baltimore, Maryland.
The New York Times reported on Wednesday that about 15 million doses were ruined, without citing a source.
"Discarding a batch of bulk drug substance, while disappointing, does occasionally happen during vaccine manufacturing, which is a complex and multi-step biological process," Emergent said.
(Reporting by Dania Nadeem in Bengaluru; Editing by Anil D'Silva)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- China-linked Japan shares shunned ahead of PM Suga's U.S. visit
- BOJ's Kuroda warns of lingering COVID pain on economy
- Myanmar security forces fire on protesting medical workers, some hurt: media